165 results about "FOXP3" patented technology

The invention provides methods of isolating CD127^lo/− immunosuppressive regulatory T cells which can be greatly enriched for FoxP3, methods of expanding the isolated cells, pharmaceutical compositions of such cells, and methods of their use in the treatment of autoimmune and other immune system mediated disorders.

Methods of treating autoimmune disorders, coronary artery disease, allergy symptoms, allograft rejection sepsis/toxic shock are disclosed. Some methods comprise administering one or more regulatory compositions to activate the T suppressor cells by increasing the acetylation level and/or protein level of FOXP3 in combination with a T suppressor stimulus and/or an antigen. Some methods comprise administering one or more regulatory compositions to activate the T suppressor cells by increasing the acetylation level and/or protein level of FOXP3. Some methods comprise administering soluble GITR or antibodies that bind to GITR ligand. Methods of treating cancer, infectious diseases, and immune deficiency are also disclosed as are vaccination methods. The methods comprise administering one or more regulatory compositions to inactivate the T suppressor cells by reducing the acetylation level and/or protein level of FOXP3. Improved vaccines and vaccination methods are disclosed. Methods of identifying compounds that are useful to modulate acetylation level and/or protein level of FOXP3 and treat diseases are disclosed.

The invention provides methods for treating autoimmunity, for reestablishing tolerance, and for generally dampening or suppressing the activation state of the immune system. The methods involve the induction or activation of a particular regulatory T cell population, characterized by its expression of CD8, CD25 and Foxp3.

The present invention relates to the treatment, diagnosis, and prophylaxis of cancer based on the expression of foxp3.

Methods for treating or preventing a Foxp3+ T regulatory cell (Treg) related disease in a subject in need thereof comprise administering to the subject an effective amount of a pharmaceutical composition comprising an inhibitor of a histone/protein acetyltransferase (HAT). Methods for identifying an agent useful for treating or preventing a Foxp3+ T regulatory cell (Treg) related disease comprise (a) contacting a candidate agent with a test sample comprising Foxp3+ T regulatory cells (Tregs), and (b) comparing a function of the Foxp3+ Tregs in the test sample with that in a control sample, wherein inhibition of the function of the Foxp3+ Tregs in the test sample when compared with the control sample indicates that the candidate agent is an agent useful for treating or preventing a Foxp3+ Treg related disease.

The present invention relates to a method, in particular an in vitro method, for pan-cancer diagnostics, comprising identifying the amount and/or proportion of stable regulatory T cells in a patient suspected of having cancer through analyzing the methylation status of at least one CpG position in the gene foxp3 and/or the gene camta1 or orthologous or paralogous genes thereof, wherein an increased amount and/or proportion of stable regulatory T cells in said patient is indicative for an unspecific cancerous disease. In a second aspect thereof, the present invention relates to a method for diagnosing the survival of a cancer patient, comprising identifying the amount and/or proportion of stable regulatory T cells in said cancer patient through analyzing the methylation status of at least one CpG position in the gene foxp3 and/or the gene camta1 or orthologous or paralogous genes thereof, wherein a demethylation in the gene foxp3 and/or the gene camta1 or orthologous or paralogous genes thereof, is indicative of a stable regulatory T cell, and wherein an increased amount and/or proportion of stable regulatory T cells in said cancer patient is indicative for a shorter survival for said cancer patient. Furthermore, the present invention relates to an improved treatment of cancers based on the inventive methods, and a kit for performing the above methods as well as respective uses.

The present disclosure provides methods for measuring the number of CD4+ OX40+ Foxp3+ lymphocytes in a sample containing cancer cells and lymphocytes obtained from a subject by labeling lymphocytes that show CD4 expression in the sample, then labeling lymphocytes that show OX40 expression in the sample, then labeling lymphocytes that show Foxp3 expression in the sample, then measuring the number of CD4+ OX40+ Foxp3+ lymphocytes in the sample. Further provided are methods for determining the prognosis of a subject, predicting responsiveness of a subject having cancer to an OX40 agonist treatment, and methods for treating or delaying progression of cancer based on the number of CD4+ OX40+ Foxp3+ lymphocytes in a sample.

The invention discloses a method for detecting an immunosuppression function of human regulatory T cells. The method comprises the following steps: collecting peripheral blood for extracting a mononuclear cell; using fluorescein marked anti-CD4 and anti-CD25 antibodies for marking a cell surface antigen; using a fixing membrane-breaking agent for fixing the cell surface antigen; after breaking the membrane, using fluorescein marked anti-Foxp3 and anti-Helios antibodies for marking endonuclear transcription factor Foxp3 and Helios; and finally, using a flow cytometry for detecting CD4+CD25+FoxP3+Helios+Treg cell population. According to the method, the function of the regulatory T cells in the peripheral blood is directly analyzed in the manner of quickly detecting the expression condition of the children peripheral blood transcription factor Helios. According to the method, the anti-Helios, anti-CD4, anti-CD25 and anti-Foxp3 flow antibodies can be used for more quickly and accurately marking the peripheral blood Treg cells with higher immunosuppression function.

In one aspect the invention relates to a method of switching the phenotype of a target cell, said method comprising inducing lineage factor activity in said cell via a transgene. In another aspect, the invention relates to a method of switching the phenotype of a target cell, said method comprising introducing to said cell a genetic element capable of inducibly generating lineage factor activity, and inducing lineage factor activity in said cell. The invention also relates to methods of suppressing immune responses and methods of treating subjects.

The invention pertains to biomedical technique field, in particular to a TGF-beta induced regulatory T-cell and a synthesis method and the applications thereof. The regulatory T-cell of the invention is formed by combining two cytokines: TGF-Beta and IL-2, and obtained by extrinsically inducing CD4+ cells of autoimmune diseases sufferer, and is recorded as CD4++CD25+Foxp3+ regulatory T-cell, wherein FoxP3 is FoxP3 gene or protein. The regulatory T-cell of the invention can be taken as a medicine preparation that is used for treating the diseases of autoimmune diseases (such as SLE) sufferer.

The invention provides a diagnostic kit for distinguishing active and latent mycobacterium tuberculosis infection with cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) serving as a diagnosis marker and a method for distinguishing active and latent mycobacterium tuberculosis infection by means of the diagnostic kit. The diagnostic kit comprises a CTLA-4, CD3, CD4, CD25, FoxP3 fluorescent antibody, erythrocyte lysate, membrane breaking liquid, washing buffer, phosphate buffer, fetal calf serum, stationary liquid and a streaming pipe. The diagnostic kit can be used for detecting the CTLA-4 expression quantity of peripheral venous blood of a patient and distinguishing active and latent mycobacterium tuberculosis infection, sensitivity and accuracy are high, and a strong basis is provided for clinic differential diagnosis.

A method for assessing risk of losing a transplanted organ by a patient having an episode of acute rejection of the transplanted organ is described. The method includes obtaining from the patient a cell sample from the transplanted organ or peripheral blood, determining a level of FOXP3 in the cell sample, and correlating the level with the risk of loss of the transplanted organ, wherein, compared to a control level, a significantly greater level of FOXP3 in the cell sample from the transplanted organ or a significantly lower level of FOXP3 in the cell sample from the peripheral blood correlates with a decreased risk of loss of the transplanted organ.

The invention provides application of a novel gamma delta T cell subpopulation to preparation of a kit for predicting the curative effect and prognosis of AML (acute myeloid leukemia). The inventor based on the invention discovers the expression condition of the novel gamma delta T cell subpopulation in peripheral blood of patients suffering from AML is associated with the curative effect and theprognosis of the patients suffering from AML for the first time. When the expression ratio of the novel PD1+Foxp3+gamma delta T cell subpopulation is high, the possibility of bad clinical curative effect of the patients suffering from AML is high. The expression ratio of the novel gamma delta T cell subpopulation has important guide significance in prognosis judgment of the patients suffering fromAML and formulation of a clinical treatment scheme. More base research data can be provided for individual treatment of the patients suffering from AML, and wide application prospect in clinical curative effect and prognosis evaluation of the patients suffering from AML is achieved.

The invention relates to application of scutelloside in pharmacy. The scutelloside promotes a T cell to be transformed toward Treg with immunological suppression effect by up-regulating the expression of Foxp3; at the same time, the scutelloside inhibits Th17 with pro-inflammatory effect and inhibits vasculitis mediated by the Th17. A main mechanism of inhibting the Th17 of the scutelloside is to inhibit the amplification of the Th17 mediated by IL-6. At the same time, a further experiment proves that the scutelloside taken as a novel immunomodulator plays good therapeutic effect on treating lupus erythenlatosus nephritis and rheumatoid arthritis.

The invention provides a detection kit to judge whether solid tumors are suited for immunotherapy. The detection kit includes detection reagents for detecting the indexes: tumor mutation load of peripheral blood circulating tumor DNA, HLA typing, HLA state of loss of heterozygosity, PD-L1 membrane expression positive tumor cell percentage, infiltration level of CD8+ immune cells, infiltration level of FOXP3+ immune cells, mRNA expression score of T-cell inflammation related genes, percentage of CD14+CD16-HLA-DR+ monocytes in peripheral blood mononuclear cells, and micro-satellite instability.The invention also provides, correspondingly, a method to judge whether solid tumors are suited for immunotherapy. The kit and method herein can be used to screen patients with solid tumors so as to provide significantly increased objective response rate and have a promising application prospect in terms of clinical screening of patients with solid tumors suited for immunotherapy.